Immunological Crossroads: Optimizing Antirejection Regimens to Sustain Antitumor Immunity in Liver Transplant Recipients with Hepatocellular Carcinoma

Chao Zhang, Xin Yuan, Kunlin XieCancers 2025 · DOI

TL;DR

Liver transplantation offers a cure for hepatocellular carcinoma (HCC), but the necessary immunosuppressants to prevent organ rejection also weaken the body's ability to fight cancer recurrence. This review explores the delicate balance between these opposing immune functions and highlights emerging strategies, from optimized drug regimens to advanced immunotherapies, to simultaneously protect the transplanted liver and combat HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a major global health challenge, and liver transplantation (LT) is a life-saving treatment for many patients. However, a critical dilemma arises post-transplant: the lifelong immunosuppressive drugs essential to prevent the body from rejecting the new liver also suppress the immune system's natural defenses against cancer. This compromised antitumor immunity significantly increases the risk of HCC recurrence, often in the lungs, leading to poor outcomes. The paper addresses the fundamental challenge of how to effectively prevent graft rejection while simultaneously preserving or even enhancing the host's ability to fight cancer recurrence.

Methods

This paper is a comprehensive review of existing literature. The authors systematically searched major databases (PubMed, Embase, Web of Science) and international conference proceedings up to September 2025. They analyzed cellular and molecular mechanisms, evaluated current immunosuppressive strategies, and explored emerging therapeutic approaches. The review synthesizes findings from preclinical studies, clinical trials, and meta-analyses to provide a theoretical basis and clinical insights.

Datasets

Not discussed in the paper. This is a review article, not a primary research study with its own datasets.

Key Insights and Ideas

  • The "Double-Edged Sword" of Immunosuppression: The core problem is that drugs designed to prevent rejection (e.g., Calcineurin Inhibitors - CNIs) broadly suppress the immune system, inadvertently creating an environment conducive to cancer recurrence.
  • Immune Cells Play Dual Roles: Many immune cells involved in rejecting foreign tissue also play a role in recognizing and eliminating cancer cells. This overlap makes non-specific immunosuppression problematic.
  • The Liver's Unique Immune Environment: The liver naturally has an immune-tolerant environment, which aids transplant success but can also facilitate HCC immune escape.
  • Beyond Global Suppression: The future lies in "context-dependent precision immune regulation," meaning strategies that selectively target rejection pathways without broadly dampening antitumor immunity.
  • mTOR Inhibitors as "Anticancer Immunosuppressants": These drugs offer a dual benefit by suppressing immune responses to the graft while also exhibiting direct antitumor effects and reshaping the tumor microenvironment.
  • Immune Checkpoint Inhibitors (ICIs) - A High-Risk/High-Reward Strategy: While effective against HCC, ICIs pose a significant risk of triggering graft rejection in transplant recipients. Careful timing (washout periods) and patient selection are crucial.
  • Adoptive Cell Therapy (ACT) - Personalized and Precise: Therapies like CAR-T cells offer highly specific targeting but require meticulous coordination with immunosuppressive regimens to avoid rejection.
  • Biomarkers are Key: Developing reliable biomarkers (e.g., Cumulative Exposure to Tacrolimus - CET) is essential for personalized risk assessment and guiding treatment decisions.

Key Results

The paper doesn't present new experimental results but synthesizes existing findings:

  • CNIs as Risk Factors: High-dose CNIs are consistently identified as independent risk factors for HCC recurrence, with cumulative exposure being a more precise predictor than trough levels.
  • MMF's Potential Antitumor Effects: Mycophenolate mofetil (MMF), while an immunosuppressant, has shown potential antitumor effects by upregulating p53, inducing S-phase arrest in HCC cells, and downregulating VEGF.
  • Steroid-Free Regimens: Early steroid withdrawal within 3-6 months post-LT is feasible and beneficial, reducing adverse effects and potentially improving survival without significantly increasing rejection risk.
  • mTOR Inhibitor Benefits: Meta-analyses show mTOR inhibitor-based regimens significantly reduce early HCC recurrence rates and improve survival compared to CNI-based regimens, with additional benefits in renal protection and reducing non-tumor-related mortality.
  • ICI Risk Stratification: Studies suggest that a washout period of less than 30 days between ICI therapy and LT significantly increases acute rejection risk, while a longer period (around 3 months) may reduce this risk.

Limitations and Future Work

  • Limitations:
    • The use of ICIs in LT recipients is still limited by the significant risk of graft rejection, and optimal management strategies are not fully established.
  • Immune heterogeneity among individuals and the lack of extensive prospective high-level evidence for novel therapies pose challenges.
  • Assessing operational tolerance (complete cessation of immunosuppressants) is complex, as some "tolerant" patients may still have subclinical graft injury.
  • Future Work:
    • Developing novel, mechanism-based selective therapeutic strategies that precisely target rejection pathways without broad immunosuppression.
  • Designing new drugs and optimizing existing ones (e.g., "anticancer immunosuppressants" like mTOR inhibitors).
  • Leveraging novel biomarkers (e.g., peripheral blood transcriptome, CET) for individualized risk stratification and treatment guidance.
  • Exploring innovative methods targeting immunometabolism and the gut-liver axis.
  • Further research into immune tolerance induction as the ultimate goal, potentially through adoptive cell therapy or nanomedicine.
  • Establishing multidisciplinary precision medicine approaches for highly individualized patient management.

Summary updated

Abstract

Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC). However, lifelong immunosuppressive therapy required to prevent graft rejection inevitably compromises antitumor immunity, thereby increasing the risk of HCC recurrence and metastasis, particularly common in the lungs. This review delves into the complex dynamic equilibrium between immune cell subsets mediating rejection and antitumor immunity, systematically analyzes the impact of current immunosuppressive regimens on this balance, and highlights emerging strategies aimed at minimizing rejection while preserving or enhancing antitumor efficacy. These strategies include immunosuppressive regimen optimization, such as mTOR inhibitor application and calcineurin inhibitor (CNI) minimization, novel immunotherapies, including immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), and immune tolerance induction. This review also summarizes advances in biomarker research guiding immunosuppressant withdrawal, aiming to provide a theoretical basis and clinical insights for personalized immunotherapy strategies and comprehensive tumor management in LT recipients with HCC.
BibTeX
@inproceedings{zhang2025immunological,
  author = {Chao Zhang and Xin Yuan and Kunlin Xie},
  title = {{Immunological Crossroads: Optimizing Antirejection Regimens to Sustain Antitumor Immunity in Liver Transplant Recipients with Hepatocellular Carcinoma}},
  booktitle = {Cancers},
  year = {2025},
  doi = {10.3390/cancers17233871},
}
Figure